Development of Enterovirus D68 3C Protease Inhibitors with In Vivo Efficacy in a Neurological Infection Model
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c00818 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Zhengjun Cai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey08854, United …. Hauptthemen laut MEDLINE: Antiviral Agents, Enterovirus D, Human, Enterovirus Infections, Protease Inhibitors. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Enterovirus D68 (EV-D68) is a non-polio enterovirus that primarily causes respiratory illness but can also lead to severe disease, including acute flaccid myelitis. No approved vaccine or antiviral is available. Here, we report the rational design and structure−property optimization of dipeptidyl EV-D68 3C protease (3Cpro) inhibitors. Structure-guided optimization and prodrug modification identified Jun13133 as a potent antiviral active against multiple contemporary EV-D68 isolates and EV-A71, with high selectivity. Computational modeling supported a stable substrate-mimetic binding mode consistent with reported covalent 3Cpro inhibitors. Jun13133 also showed favorable in vivo pharmacokinetic properties. In a neonatal mouse model of EV-D68-induced neurological disease, Jun13133 mitigated paralysis, prevented weight loss, and reduced viral replication in spinal cord and muscle tissues. These results validate EV-D68 3Cpro as a druggable antiviral target and support Jun13133 as a promising lead for further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey08854, United States.
- Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado80045, United States.
- Department of Immunology & Microbiology, University of Colorado School of Medicine, Aurora, Colorado80045, United States.
- Division of Infectious Disease, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado80045, United States.
- Neurology Service, Rocky Mountain VA Medical Center, Aurora, Colorado80045, United States.
ORCID-Profile: Jun Wang
Förderung
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Cai, Z., Rudy, M., Li, K., Tan, H., Fan, G., Clarke, P., Tyler, K., & Wang, J. (2026). Development of Enterovirus D68 3C Protease Inhibitors with In Vivo Efficacy in a Neurological Infection Model. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c00818
Vancouver
Cai Z, Rudy M, Li K, Tan H, Fan G, Clarke P, et al. Development of Enterovirus D68 3C Protease Inhibitors with In Vivo Efficacy in a Neurological Infection Model. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c00818
BibTeX
@article{Cai2026,
author = {Cai, Zhengjun and Rudy, Michael and Li, Kan and Tan, Haozhou and Fan, Guangjin and Clarke, Penny and Tyler, Kenneth and Wang, Jun},
title = {Development of Enterovirus D68 3C Protease Inhibitors with In Vivo Efficacy in a Neurological Infection Model},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c00818}
}
EUVIMED